The level of IL-6 is elevated in the central nervous system of MS patients and EAE mice, while IL-6 inhibitors can inhibit the differentiation of Th1 and Th17 cells and reduce the pathogenesis of EAE (Serada et al. 2008). Here, IL6 is linked to myeloid sarcoma.